Home > Financial Ratios > NATCO PHARMA

NATCO PHARMA
Core EBITDA Growth

    Back to All Ratios
NATCO PHARMA is part of below Screeners ↓
Top Undervalued Small Cap Stocks
Best Quarterly Growth Small Cap Stocks
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results

NATCO PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2024Mar2023Mar2022Mar2021Mar2020
   Core EBITDA Growth(%) 80.69186.95-48.932.87-25.41

What is the latest Core EBITDA Growth ratio of NATCO PHARMA ?

The latest Core EBITDA Growth ratio of NATCO PHARMA is 80.69 based on Mar2024 Consolidated results.
Year Core EBITDA Growth
Mar202480.69
Mar2023186.95
Mar2022-48.93
Mar20212.87
Mar2020-25.41

How is Core EBITDA Growth of NATCO PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2024 80.69
-56.84
Mar2023 186.95
Positive
Mar2022 -48.93
Negative
Mar2021 2.87
Positive
Mar2020 -25.41 -

Other Financial Ratios of NATCO PHARMA


Compare Core EBITDA Growth ratio of peers of NATCO PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
NATCO PHARMA ₹22,124.2 Cr 6.4% -6.9% 35.3% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹423,974.0 Cr 1.3% -4.7% 22.8% Stock Analytics
DIVIS LABORATORIES ₹161,729.0 Cr 6.3% 3.3% 59.2% Stock Analytics
CIPLA ₹116,999.0 Cr -0.7% -3.3% 2.1% Stock Analytics
DR REDDYS LABORATORIES ₹101,771.0 Cr 2.1% -9.7% -0.3% Stock Analytics
ZYDUS LIFESCIENCES ₹97,951.9 Cr 2.1% -2.8% 26.4% Stock Analytics


NATCO PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
NATCO PHARMA

6.4%

-6.9%

35.3%

SENSEX

2.7%

0.8%

9.7%


You may also like the below Video Courses